

Q1 2019 RESULTS

OLIVIER BRANDICOURT

CHIEF EXECUTIVE OFFICER, SANOFI



“Our strong first quarter performance is a continuation of the momentum that began in the second half of 2018”

COMPANY SALES & BUSINESS EPS*

Q1 2019 SALES*

€8,391M

+4.2% (+6.2%)

Q1 2019 BUSINESS EPS*

€1.42

+9.4% (+10.9%)

*Growth rates are expressed at constant exchange rates (CER). Growth rate in parentheses are expressed on a reported basis.

SALES BY GLOBAL BUSINESS UNIT



€2,285M

Primary Care



€2,019M

Sanofi Genzyme (Specialty Care)



€1,958M

China & Emerging Markets



€1,256M

Consumer Healthcare



€873M

Sanofi Pasteur (Vaccines)

SALES BY GEOGRAPHY

- 1 U.S. €2,550M
 - 2 EUROPE €2,187M
 - 3 LATIN AMERICA €615M
 - 4 EURASIA* €312M
 - 6 ASIA €1,206M
 - 6 AFRICA & MIDDLE EAST €556M
- ROW** €924M



*Eurasia: Russia, Ukraine, Georgia, Belarus, Armenia and Turkey
 **Rest of the World: Japan, South Korea, Canada, Australia, New Zealand and Puerto Rico.

R&D HIGHLIGHTS

84

projects in development, including new molecular entities & additional indications

35

projects in Phase 3 or submitted for approval

FOR ADDITIONAL INFORMATION ON Q1 2019 RESULTS AND DEFINITIONS OF FINANCIAL INDICATORS, PLEASE REFER TO THE PRESS RELEASE ISSUED ON APRIL 26, 2019 AT:

[HTTPS://WWW.SANOFI.COM/EN/INVESTORS](https://www.sanofi.com/en/investors)

SANOFI.COM



@Sanofi



Sanofi



@Sanofi

SANOFI.US



@SanofiUS



SanofiUS